Diabetic Foot Files

Welcome to LIMBWatch — the global movement dedicated to protecting limbs, preventing amputations, and transforming the future of diabetic foot care.

In this landmark episode, we welcome one of the world’s most influential leaders in diabetes and diabetic foot disease — Dr. Andrew Boulton, a pioneer whose research, leadership, and advocacy have shaped modern approaches to neuropathy, diabetic foot screening, and limb salvage.

With more than 600 peer-reviewed publications, an H-index exceeding 130, and decades of international leadership including roles with global diabetes organizations, Dr. Boulton shares lessons from a lifetime dedicated to one mission: preventing unnecessary amputations and improving the lives of people living with diabetes worldwide.

In this powerful conversation, Dr. Boulton discusses:

🦶 Why diabetic neuropathy can remain silent until it is too late
🦶 The life-changing importance of annual diabetic foot screening
🦶 Why “take off the shoes and socks and look at the feet” remains one of the most powerful tools in medicine
🦶 The misconception that amputation is an inevitable outcome of diabetic foot disease
🦶 How multidisciplinary foot teams can transform limb salvage outcomes
🦶 Why prevention must become the future of diabetic foot care
🦶 The role of AI and technology in identifying high-risk patients
🦶 Why evidence-based medicine is essential for advancing wound healing treatments
🦶 The overlooked importance of footwear, offloading, biomechanics, and patient-centered care
🦶 The future of global diabetic foot initiatives and making limb preservation accessible everywhere

Dr. Boulton also shares personal reflections from his career, including lessons learned from patients, his admiration for pioneers like Dr. Paul Brand, and why the greatest reward in medicine is not financial success — but the ability to change lives.

His message is clear:

Diabetic foot complications are preventable. Screening saves limbs. Early intervention saves lives.

This episode is a must-listen for healthcare professionals, patients, researchers, policymakers, and anyone committed to building a future where amputations become less common and limb salvage becomes the global standard.

This is LIMBWatch — because every limb matters.

This episode clarifies the difference between antimicrobials (agents that act against a range of microorganisms) and antibiotics (drugs that specifically target bacteria), and explains related terms like antiseptics, contamination, colonization, and infection in diabetic foot ulcers.

Dr. G reviews when topical antimicrobial dressings are appropriate, why they do not automatically replace systemic antibiotics, and how debridement, source control, and wound biology guide treatment decisions.

Key takeaways focus on evaluating the wound, understanding product mechanisms, avoiding unnecessary antibiotics through stewardship, and choosing interventions that help heal the patient and protect the limb.

This episode explains why healed wounds can feel tight, covering the stages of wound healing, the role of myofibroblasts and alpha-SMA in wound contraction, and how scar tissue differs from normal skin.

It discusses how diabetes alters healing, the long remodeling phase (months to over a year), practical care tips like moisturization and follow-up, and warning signs that require prompt medical attention.

This episode explores Rhodococcus equi — a pink, soil‑associated bacterium historically linked to horses that can survive inside macrophages and mimic tuberculosis in the lungs.

Dr. G discusses its discovery, how humans become exposed, diagnostic clues (culture, MALDI‑TOF, PCR), challenges in treatment (intracellular survival, prolonged combination antibiotics, and need for surgical source control), and its importance in immunocompromised and diabetic foot wound patients.

This episode traces the history and science behind triple antibiotic ointment—its three ingredients (bacitracin, neomycin, polymyxin B), how they attack different bacteria, and why it became a household staple for minor cuts.

It explains why diabetic foot ulcers are fundamentally different from everyday wounds—driven by neuropathy, poor blood flow, chronic inflammation, biofilm, and deeper infection—and why a topical ointment cannot address these underlying problems.

The episode also covers risks of using ointment on diabetic ulcers (maceration, contact dermatitis, altered wound microbiome), the difference between colonization and infection, and the importance of prompt medical assessment, vascular evaluation, offloading, debridement, glucose control, and specialized wound care.